Abstract
Results There were a total of 60 patients who were followed up. Three patients in Group II were removed from the analysis as they underwent total knee arthroplasty (TKA). A notably significant improvement was noticed in the ABMDC group on all scores of VAS and MKSSSF with P < 0.0001. The control group continued to be dissatisfied with the treatment they were taking. Conclusions This study reveals that a single injection of 5 million of ABMDC was efficient in reducing the symptoms, improving the functional score and betterment of QOL.
Highlights
Osteoarthritis of the knee (OAK) is usually due to aging process, and many factors influence the severity of the disease. e prevalence of OAK of the knee is unknown, but recently, it was reported that over 12.5% of the population over 45 years of age suffer from OAK. [1] e incidence of OAK in Saudi Arabian population was found to be up to 3.5% [2, 3], but recent reports indicate that the prevalence of clinical OAK increased many folds to 13% [4] and radiological OA of knee to 53% in males and 60.9% in females [5]
A control group of 27 patients were treated with nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and Durolane, a hyaluronic acid injection. e demographic data of patients in groups I and II were similar before the treatment was instituted
Our preliminary study showed that autologous bone marrow-derived chondrocytes (ABMDCs) intra-articular injection in KL II and III grade knees showed an excellent improvement compared to the patients in the standard treatment protocol
Summary
Osteoarthritis of the knee (OAK) is usually due to aging process, and many factors influence the severity of the disease. e prevalence of OAK of the knee is unknown, but recently, it was reported that over 12.5% of the population over 45 years of age suffer from OAK. [1] e incidence of OAK in Saudi Arabian population was found to be up to 3.5% [2, 3], but recent reports indicate that the prevalence of clinical OAK increased many folds to 13% [4] and radiological OA of knee to 53% in males and 60.9% in females [5].e OAK is traditionally managed using nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and nutritional supplements [6,7,8,9,10,11,12]. e response to such treatment is not always absolute and requires steroid and hyaluronic acid injections and arthroscopic joint washout with diverse degrees of pain relief [13, 14].In the recent past, incidence of OAK has increased, but no new modes of management have been added apart from the symptomatic treatment with NSAIDs and physical therapy. Jo et al [17] reported that after injecting MSCs into the osteoarthritic knee, follow-up at 3, 6, and 12 months showed improvement in function and total relief of pain of the knee joint without causing adverse events and reduced cartilage defects by regeneration of the cartilage, which was similar to hyaline cartilage histologically. Soler et al [18] reported the outcome of autologous MSCs in patients with grades II and III of Kellgren–Lawrence grading and found that a single intra-articular injection of the MSCs was safe and gave complete pain relief with improved quality of life with signs of cartilage repair based on the MRI. E aim of this study was to compare the effect of autologous bone marrow-derived chondrocytes (ABMDCs) with pharmacological management of osteoarthritis of knee (OAK) and assess the benefit of the two in the improvement of pain relief, functional betterment, and quality of life (QOL). Conclusions. is study reveals that a single injection of 5 million of ABMDC was efficient in reducing the symptoms, improving the functional score and betterment of QOL
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
